Vinay Prasad is poised to become the director of CBER at the FDA, a role crucial for vaccine approval. His past statements show opposition to COVID vaccines for children, concerns over U.S. vaccination rates, and belief in loosening manufacturer liability. Critics argue his views may exacerbate vaccine hesitancy, undermining public health initiatives.
What Has Vinay Prasad Said About Vaccines? Read More »
Testing new vaccines with saline placebos may seem beneficial, but ethical concerns arise when existing vaccines are available. Trials should prioritize participants’ safety, providing them with alternatives rather than depriving them of protection. Misunderstandings about placebo use could hinder vaccine approval and public health efforts, highlighting the complexity of vaccine trial ethics.
Should All New Vaccines Require Testing With a Saline Placebo? Read More »
Some people falsely argue that hepatitis B vaccines were approved with inadequate trials. This misinformation is deceitful, as extensive studies were conducted before approval, with ongoing monitoring for adverse effects. Post-marketing studies and long-term data affirm the safety and efficacy of hepatitis B vaccines, debunking unfounded claims propagated by anti-vaccine influencers.
Were Hepatitis B Vaccines Approved With Invalid Trials? Read More »
You must be logged in to post a comment.